in the absence of a submission from the holder of the marketing authorisation:
sofosbuvir (Sovaldi®) is not recommended for use within NHS Scotland.
Indication under review: In combination with other medicinal products for the treatment of chronic hepatitis C in adolescents aged 12 to <18 years.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this setting. As a result we cannot recommend its use within NHSScotland.
From January 2020, ADTCs may make formulary decisions on paediatric licence extensions for medicines previously accepted for use (or restricted use) for the corresponding indication in adults, taking account of relevant restrictions. This approach may also be applied retrospectively to medicines accepted for use in adults but not recommended in the corresponding indication in children due to absence of submission. PASAG liaises with companies to extend any PAS to include the younger age group and confirms arrangements with Boards.
Download detailed advice135KB (PDF)
- Medicine name:
- sofosbuvir 400mg film-coated tablets (Sovaldi)
- SMC ID:
In combination with other medicinal products for the treatment of chronic hepatitis C in adolescents aged 12 to <18 years.
- Pharmaceutical company
- Gilead Sciences Ltd
- BNF chapter
- Submission type
- Non submission
- Not recommended
- Date advice published
- 12 March 2018